EUVIMEDEUVIMED entdecken
Crossref

Interplay of Multipathway Dyslipidemia, Inflammation, and Cholesterol-Lowering Medication in Modifying Abdominal Aortic Aneurysm Risk

Yiting Wu iD, Dan Chen iD, Yanjun Zhang iD, Ziliang Ye, Sisi Yang iD, Xiaoqin Gan iD, Yu Huang iD, Yiwei Zhang iD, Xianglian Cai, Xiaolong Liang, Yuanyuan Zhang iD, Xianhui Qin iD

Arteriosclerosis, Thrombosis, and Vascular Biology · 2026

DOI: 10.1161/atvbaha.126.324423 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2026. Verfasst von Yiting Wu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Nanfang Hospital, Southern Medical University, National Clinical Research Center for Kidney and Urological Diseases, State Ke…. Hauptthemen laut MEDLINE: Aortic Aneurysm, Abdominal, Dyslipidemias, Inflammation, Anticholesteremic Agents. Die Arbeit nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Abdominal aortic aneurysm (AAA) carries high rupture mortality, yet medical therapies remain limited. While dyslipidemia and inflammation are implicated in AAA pathogenesis, the individual and joint roles of key lipid fractions, LDL-C (low-density lipoprotein-cholesterol), Lp(a) (lipoprotein[a]), and remnant cholesterol (RC), with systemic inflammation, are not fully established, particularly in the context of widespread cholesterol-lowering medication use. METHODS: We performed a prospective analysis of 338 758 UK Biobank participants free of AAA at baseline. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% CIs for associations between biomarkers and incident AAA. RESULTS: Over a median follow-up of 13.65 years, 1694 incident AAA cases occurred. Among participants not taking cholesterol-lowering medication, concurrent elevations of LDL-C, Lp(a), and RC (>75th percentile) conferred the highest risk (adjusted HR, 2.53 [95% CI, 1.97–3.24]). Coexisting elevated Hs-CRP (high-sensitivity C-reactive protein) with this triple-lipid elevation further increased the risk (adjusted HR, 4.19 [95% CI, 2.97–5.91]). Among cholesterol-lowering medication users, significant associations persisted for LDL-C (adjusted HR, 1.19 [95% CI, 1.09–1.29]) and RC (adjusted HR, 1.22 [95% CI, 1.14–1.31]) but not for Lp(a) (adjusted HR, 1.03 [95% CI, 0.97–1.10]). In this group, the combination of elevated LDL-C, RC, and Hs-CRP was associated with the greatest risk (adjusted HR, 2.46 [95% CI, 1.86–3.26]). CONCLUSIONS: Combined elevations of multiple lipid fractions and systemic inflammation were associated with a substantially increased risk of AAA. Cholesterol-lowering medication was associated with an attenuated risk relationship for LDL-C and Lp(a) but not for RC or Hs-CRP. Comprehensive risk assessment integrating a full lipid profile and Hs-CRP can improve identification of high-risk phenotypes for targeted AAA prevention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aortic Aneurysm, AbdominalDyslipidemiasInflammationAnticholesteremic AgentsHumansMaleFemaleRisk FactorsProspective StudiesAgedBiomarkersLipoprotein(a)Risk AssessmentMiddle AgedUnited KingdomCholesterol, LDLIncidenceC-Reactive ProteinCholesterolTime FactorsInflammation Mediators

Stichwörter der Autor:innen

aortic aneurysm, abdominalcardiovascular diseasesdyslipidemiasinflammationlipoprotein(a)

Substanzen

BiomarkersLipoprotein(a)Cholesterol, LDLAnticholesteremic AgentsC-Reactive ProteinLPA protein, humanCholesterolInflammation Mediators

Autor:innen und Institutionen

  • Division of Nephrology, Nanfang Hospital, Southern Medical University, National Clinical Research Center for Kidney and Urological Diseases, State Key Laboratory of Multi-Organ Injury Prevention and Treatment, Guangdong…

ORCID-Profile: Yiting Wu, Dan Chen, Yanjun Zhang, Sisi Yang, Xiaoqin Gan, Yu Huang, Yiwei Zhang, Yuanyuan Zhang, Xianhui Qin

Zitieren

APA

Wu, Y., Chen, D., Zhang, Y., Ye, Z., Yang, S., Gan, X., Huang, Y., Zhang, Y., Cai, X., Liang, X., Zhang, Y., & Qin, X. (2026). Interplay of Multipathway Dyslipidemia, Inflammation, and Cholesterol-Lowering Medication in Modifying Abdominal Aortic Aneurysm Risk. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.126.324423

Vancouver

Wu Y, Chen D, Zhang Y, Ye Z, Yang S, Gan X, et al. Interplay of Multipathway Dyslipidemia, Inflammation, and Cholesterol-Lowering Medication in Modifying Abdominal Aortic Aneurysm Risk. Arteriosclerosis, Thrombosis, and Vascular Biology. 2026. doi:10.1161/atvbaha.126.324423

BibTeX
@article{Wu2026,
  author = {Wu, Yiting and Chen, Dan and Zhang, Yanjun and Ye, Ziliang and Yang, Sisi and Gan, Xiaoqin and Huang, Yu and Zhang, Yiwei and Cai, Xianglian and Liang, Xiaolong and Zhang, Yuanyuan and Qin, Xianhui},
  title = {Interplay of Multipathway Dyslipidemia, Inflammation, and Cholesterol-Lowering Medication in Modifying Abdominal Aortic Aneurysm Risk},
  journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
  year = {2026},
  doi = {10.1161/atvbaha.126.324423}
}
Kostenlos starten →